Randomized Clinical Trial PULVAB (Prophylactic Pulmonary Veins Ablation)

Multicenter Randomized Clinical Trial PULVAB (Prophylactic Pulmonary Veins Ablation)

To compare prophylactic strategies of atrial fibrillation in patients with CAD and without AF.

Prospective, multicenter, randomized trial, intended to compare three prophylactic strategies of atrial fibrillation in patients with coronary artery disease and without history of atrial fibrillation.

The study includes 4 groups of patients:

Group I (conventional CABG)

Group II (CABG + pulmonary veins isolation). Concomitant CABG and epicardial bipolar radiofrequency pulmonary veins isolation.

Group III (CABG+ pulmonary veins isolation + amiodarone). Concomitant CABG and epicardial bipolar radiofrequency pulmonary veins ablation with administration of amiodarone in postoperative periode.

Group IV (CABG+ amiodarone). Conventional CABG with administration of amiodarone in postoperative periode.

Inclusion Criteria:

• patients must have signed an informed consent.
• patients had indications for two or more coronary arteries to be bypassed
• no history of AF

Exclusion Criteria:

• acute coronary syndrome
• previous CABG.
• a significant decrease in the contractile function of the heart (EF <40%)
• significant heart valve disease requiring surgical repair
• long-standing persistent, persistent, or paroxysmal forms of atrial fibrillation
• respiratory failure
• left ventricular aneurysm requiring surgical correction
• chronic renal failure (≤60 mL/min/1⋅73 m2)
• chronic diseases that make a significant contribution to the prognosis of life (e.g. oncology)
• participation in other clinical trials